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microRNAs (miRNAs), a newly 
characterized class of regulatory genes, 
have revolutionized classical biomolecu-
lar principles. These small non-coding 
RNAs, which are around 22 nucleotides 
long, negatively regulate gene expression 
through translational repression or target-
ing mRNAs for degradation. miRNAs 
function in multiple cellular processes, 
including proliferation, differentiation, 
and apoptosis, and their deregulation is 
a hallmark of human diseases including 
cancer.1
Cancers that are resistant to conven-
tional therapies often advance to metasta-
sis, which further complicates successful 
treatment. In this process, genetic and epi-
genetic instability, as well as a capacity for 
self-renewal, allow malignant cancer cells 
to escape from the primary tumor and 
colonize secondary sites. The discovery 
of the contribution of epigenetic altera-
tions in tumorigenesis has been of enor-
mous importance to our understanding of 
cancer pathogenesis; hence, it is tempting 
to speculate that epigenetic mechanisms 
may also regulate miRNA-encoding genes 
involved in triggering the metastatic pro-
cess. What is still not known, however, is 
whether and how miRNAs can directly 
modulate the epigenetic cancer landscape.
Indeed, we recently found that miR-
22 acts as a very potent proto-oncogenic 
miRNA precisely because of its ability to 
epigenetically derange the biology of the 
cell. Intriguingly, we have shown that miR-
22 antagonizes another critical miRNA, 
the anti-metastatic mir-200 gene, through 
direct targeting of the methylcytosine 
dioxygenase TET (ten-11 translocation) 
family members and, hence, chromatin 
remodeling toward miR-200 transcrip-
tional silencing.2
Using Cre-based mammary gland-spe-
cific transgenic mouse model, we further 
demonstrated that miR-22 triggers epi-
thelial–mesenchymal transition (EMT), 
enhances stemness, and promotes breast 
cancer development and metastasis.2 
Moreover, miR-22 promotes aggressive 
metastatic disease in neu (ErbB2; Her2) 
or PyVT oncogene compound mice. We 
show that miR-22 exerts this metastatic 
potential by increasing methylation of the 
mir-200 promoter, thus suppressing the 
expression of the anti-metastatic miR-200 
family.
Through extensive bioinformatic and 
experimental analyses, we identified the 
TET family as the cognate target of miR-
22 that is essential to the demethylation 
of the mir-200 promoter. In keeping with 
this notion, high expression of miR-22 has 
been found to correlate with poor clini-
cal outcomes and silencing of the TET-
miR-200 axis in human breast cancer 
patients.2
In a back-to-back study, we have identi-
fied miR-22 as a key regulator of the self-
renewal machinery of the hematopoietic 
system.3 miR-22 was found to reduce the 
global level of 5-hydroxymethylcytosine 
(5-hmC) in the genome of mouse hemato-
poietic stem cells (HSCs), which triggered 
an increase in HSC self-renewal capability 
accompanied by defective differentiation 
and the development of a human myelo-
dysplastic syndrome (MDS)-like disease, 
followed by the development of hemato-
logical malignancies at full penetrance.3 
Again we identified TET2 as a critical tar-
get of miR-22 in this context, as an ectopic 
expression of TET2 suppressed the pheno-
types caused by miR-22 overexpression. 
Interestingly, miR-22 appears to be over-
expressed in human MDS and leukemia, 
and its aberrant expression correlates with 
poor survival of patients and TET2 down 
regulation.
Several previous in vitro studies have 
suggested a tumor suppressive role for 
miR-22, but corroboration of its onco-
genic potential has also been found in 
human prostate cancer and mouse models 
of cardiac hypertrophy through the target-
ing of the PTEN (phosphatase tensin and 
homolog) tumor suppressor.4,5 It is worth 
noting, however, that the function of miR-
22 as an epigenetic modifier in breast can-
cer metastasis appears to be independent 
of its ability to target PTEN.2 However, 
it is possible that the ability of miR-22 to 
simultaneously repress PTEN and TET2 
may confer on it a unique ability to over-
come PTEN loss-driven HSC exhaustion 
while favoring MDS development and 
leukemogenesis.3
One of the most exciting findings 
arising from our work is that the TET-
mediated chromatin remodeling activity 
of miR-22 uncovers a chromatin remod-
eling antagonism between miRNAs. As 
numerous miRNAs appear to be altered 
in cancer, it will be interesting to deter-
mine whether the miR-22-TET network 
contributes to genome-wide epigenetic 
regulation of miRNAs in cancer and stem 
cell biology. On the other hand, it will 
also be interesting to assess how miR-22 
modulates TET-mediated DNA demeth-
ylation vs. miR-200-Bmi1 (B lymphoma 
Mo-MLV insertion region 1 homolog) 
polycomb protein-mediated chromatin 
remodeling.
More fundamental questions arising 
from these studies would be related to 
the causes of aberrant expression of miR-
22 in the pathogenesis of cancer metas-
tasis and blood disease. Therefore, the 
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identification of the oncogenic or tumor-
suppressive upstream regulators of miR-
22 is of critical importance. Interestingly, 
previous studies have demonstrated that 
the PI3K/AKT pathway activates mir-22 
gene transcription; miR-22 is also acti-
vated by the transcription factor Myc and, 
in turn, inhibits the Myc transcriptional 
repressor MXD46,7 (Fig. 1).
Ultimately, as the technology to inhibit 
miRNAs for therapy is rapidly evolving,8 
these findings could lead to treatment 
options for a range of diseases in the years 
to come. Indeed, our findings that inhib-
iting miR-22 by the miR-22 decoy leads 
to a reduction of metastatic phenotypes 
in the breast, while LNA (locked nucleic 
acid)-modified miR-22 decoy results in 
a signification reduction in leukemic cell 
proliferation; together these findings sup-
port LNA-based targeting of miR-22 as a 
potential treatment modality for human 
tumorigenesis and metastasis.
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Figure  1. mir-22 directly targets PtEN and 
tEt to promote tumorigenesis and metasta-
sis. While mir-22 impacts cancer development 
through targeting of the PtEN tumor suppres-
sor, mir-22 triggers EMt and metastasis and 
stem cell self-renewal via tEt-mediated chro-
matin remodeling. mir-22 is activated by the 
Pi3K/aKt pathway with a positive feedback 
loop. mir-22 is also one of the mirNas that is 
regulated by the proto-oncogenic transcrip-
tion factor, Myc.
